6个月内早期前列腺特异性抗原应答可预测转移性激素敏感性前列腺癌的治疗效果:TITAN试验的探索性分析
本研究为TITAN试验的二次分析,旨在评估早期PSA应答(6个月内PSA≤0.2 ng/mL)能否预测转移性激素敏感性前列腺癌(mHSPC)的治疗效果。结果显示,6个月PSA应答者在阿帕他胺组与单独ADT组的总生存期(OS)存在显著交互作用(交互P=0.03),应答者HR为0.66(95%CI 0.44-1.00),非应答者HR为1.14(95%CI 0.89-1.46)。
要点
- 6个月时PSA≤0.2 ng/mL的早期应答率在阿帕他胺组为61%(321/524),在单独ADT组约为24%(124/524)。
- 6个月PSA应答者中,阿帕他胺组较单独ADT组3年OS分别为84%(80%-88%)vs 74%(66%-82%)。
- 阿帕他胺对OS的治疗效应在6个月PSA应答者(HR 0.66;95%CI 0.44-1.00)与非应答者(HR 1.14;95%CI 0.89-1.46)间存在显著差异(交互P=0.03)。
核心结论
- 6个月内早期PSA应答是ADT联合阿帕他胺对mHSPC患者OS治疗获益的预测因素。
- 在阿帕他胺组中,早期PSA应答时间越长与更优的OS显著相关。
研究设计与样本
- TITAN试验的二次分析(探索性分析),纳入转移性激素敏感性前列腺癌患者。
- 早期PSA应答定义为随机分组后6个月内达到PSA≤0.2 ng/mL。
- 采用带有治疗与早期PSA应答交互项的Cox比例风险模型在界标人群中分析OS差异。
- 应用多变量Cox比例风险回归模型,以限制性立方样条拟合早期PSA应答时间,分析其与OS的关联。
主要发现
- 约24%(124/524)的单独ADT组患者和61%(321/524)的阿帕他胺组患者在6个月内达到PSA≤0.2 ng/mL。
- 在阿帕他胺组中,早期PSA应答时间越长与显著更优的OS相关。
- 6个月PSA应答者中,阿帕他胺对OS的治疗效应与非应答者存在显著差异(交互P=0.03):应答者HR 0.66(95%CI 0.44-1.00)vs 非应答者HR 1.14(95%CI 0.89-1.46)。
- 该治疗效应差异在3个月时未达统计学显著(交互P=0.17)。
- 6个月PSA应答者中,3年混杂因素校正OS在阿帕他胺组为84%(80%-88%),单独ADT组为74%(66%-82%)。
关键数值与推荐
- 早期PSA应答定义为随机分组后6个月内PSA≤0.2 ng/mL。
- 6个月PSA应答者:阿帕他胺组HR 0.66(95%CI 0.44-1.00);非应答者HR 1.14(95%CI 0.89-1.46);交互P=0.03。
- 3个月时交互作用P=0.17,未达统计学显著。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Early PSA response has been found to be prognostic of outcomes in metastatic hormone sensitive prostate cancer. We performed a secondary analysis of the TITAN trial to determine if early PSA response was predictive of treatment efficacy in metastatic hormone sensitive prostate cancer patients. MATERIALS AND METHODS: Early PSA response was defined as achieving a PSA level of ≤ 0.2 ng/mL by 6 months of random assignment. A Cox proportional hazard model was constructed in a landmark population with an interaction term between the treatment and early PSA response to determine differential treatment effect on overall survival (OS). We applied multivariable Cox proportional hazard regression model with time to early PSA response fitted with restricted cubic spline to determine the association of time to early PSA response with OS. RESULTS: Approximately 24% (124/524) of patients in the androgen deprivation therapy (ADT) alone group and 61% (321/524) in the apalutamide group had PSA response ≤ 0.2 ng/mL by 6 months. Longer time to early PSA response was associated with significantly superior OS in the apalutamide group. There was a significant difference in treatment effect from apalutamide on OS (P = .03 for interaction) among 6-month PSA responders (HR: 0.66; 95% CI: 0.44-1.00) vs nonresponders (HR: 1.14; 95% CI: 0.89-1.46). This difference in treatment effect was not statistically significant at 3 months (P = .17 for interaction). Among 6-month PSA responders, 3-year confounder-adjusted OS was 84% (80%-88%) for the apalutamide group and 74% (66%-82%) for the ADT alone group. Among nonresponders, 3-year adjusted OS for the 2 treatment arms were 58% (52%-65%) and 56% (51%-60%), respectively. CONCLUSIONS: Early PSA response by 6 months was a predictor of treatment efficacy from ADT plus apalutamide on OS. Longer time to early PSA response was associated with superior OS in the apalutamide arm.
引用
- Roy S, Sun Y, Chi KN, et al. Early Prostate-Specific Antigen Response by 6 Months Is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of the TITAN Trial. J Urol. 2024. PMID: 39058790. doi:10.1097/JU.0000000000004158
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。